Oxidative StressNCT04061070
Effects of Trehalose and Polyphenols in Vasculopathic Patients
A study testing Supplementation with mix of threalose plus polyphenols and No Supplementation with mix of threalose plus polyphenols in people with Oxidative Stress and Cardiovascular Diseases, run by University of Roma La Sapienza at 2 sites in Italy.
Trial summary
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis and is characterized by obstruction of the arteries of the lower extremities. PAD is usually associated with vascular complications that occur not only in peripheral circulation but also in cerebral and coronary trees (PubMed… Read more about this study
- Who is it for?
- Ages 60 to 80 years
- Conditions the study is for
- Oxidative Stress, Cardiovascular Diseases
- What is being tested?
- Supplementation with mix of threalose plus polyphenols and No Supplementation with mix of threalose plus polyphenols
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 2 sitesItaly
- Study dates
- 12 Dec 2019to 30 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- claudication (defined as pain in the legs during walking which disappears within 10 minutes of standing);
- ankle/brachial index (ABI), evaluated as an ankle/arm systolic blood pressure ratio using Doppler ultrasound on the worst resting leg;
- stable condition without sudden changes in ABI (> 20%) in the last month before enrollment
- Office systolic BP (SBP) values ≥140 mmHg and/or diastolic BP (DBP) values ≥90 mmHg (average of 3 repeated measurements made by the same doctor with an oscillometric automatic sphygmomanometer). Treatment with antihypertensive drugs, namely ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), thiazide/thiazide-like diuretics, loop diuretics, mineralocorticoid receptor antagonists (MRA), beta-blockers and alpha-blockers, were considered hypertensives.
Who cannot join
- liver failure;
- severe kidney disorders (serum creatinine [mt] 2.8 mg / dL);
- acute cerebrovascular disease;
- acute myocardial infarction;
- smokers;
- patients under treatment with antioxidants for at least 30 days before enrollment
- Patients with diabetes mellitus or known history of ischemic heart disease, peripheral artery disease, and chronic renal failure were excluded.
Trial locations and contacts
2 sites in 1 country.
Italy2 sites
Umberto I Policlinico di Roma, Sapienza Università di Roma
Roma, Italia, 00155
Umberto I Policlinico di Roma, Sapienza Università di Roma
Rome, 00155
About this study
Official title: Effects of Trehalose and a Mix of Polyphenols on Endothelial Function, Oxidative Stress, Platelet Function and Autophagy in Vasculopathic Patients
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis and is characterized by obstruction of the arteries of the lower extremities. PAD is usually associated with vascular complications that occur not only in peripheral circulation but also in cerebral and coronary trees (PubMed ID: 9892517). Endothelial dysfunction, reduced glucose oxidation, accumulation of toxic metabolites, alteration in nitric oxide (NO) generation and oxidative stress seem to play a role among the factors that contribute to reducing blood flow in PAD patients (PubMed ID: 17298965).
Hypertension is a risk factor for vascular disorders, including PAD. In fact, it has been shown that 55% of PAD patients are hypertensive. (PubMed ID: 15579058) PAD and hypertension patients have a risk of cardiovascular and cerebrovascular mortality increased two to three times compared to healthy subjects. The alteration of platelet function is implicated in the development and progression of atherosclerosis, as well as in the pathogenesis of acute cardiac ischemic events. Platelet activation is increased in patients with PAD and hypertension compared to healthy controls, suggesting a pro-thrombotic state.
Read more
Polyphenols are a class of natural, synthetic and semisynthetic substances with beneficial effects on human health. In particular, the polyphenols exert their beneficial effect through 1) the inhibition of NADPH oxidase (Nox2), which is crucial for the formation of reactive oxygen species (ROS); 2) an antiplatelet effects 3) the activation of autophagy. Trehalose is a natural disaccharide that performs multiple functions such as a protective action against oxidative stress, temperature changes, accumulation of protein aggregates and dehydration. Furthermore, recent evidence has shown that trehalose could prevent inflammatory responses induced by endotoxic shock both in vivo and in vitro.
Therefore the purpose of this work will be to determine in PAD and hypertension patients the effect of the intake of trehalose and a polyphenol mix on oxidative stress biomarkers, autophagic activity and endothelial dysfunction.
Read the detailed description
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis and is characterized by obstruction of the arteries of the lower limbs. PAD is usually associated with vascular complications that occur not only in peripheral circulation but also in cerebral and coronary trees (PubMed ID: 9892517). Intermittent claudication, the typical clinical manifestation of the disease that affects about a third of PAD patients, is identified by an alteration in blood flow to the lower extremities during exercise, worsens in 25% of patients and about 5% suffers an amputation (PubMed ID: 2647761). Arteries, arterioles, and capillaries that serve the skeletal muscle tissue distal to the site of the stenosis play a key role in the onset of claudication. Endothelial dysfunction, reduced glucose oxidation, accumulation of toxic metabolites, alteration in nitric oxide (NO) generation and oxidative stress seem to play a role among the factors that contribute to reducing blood flow in PAD patients (PubMed ID: 17298965). Nitric oxide (NO) is synthesized by L-arginine, is constitutively released by endothelial cells and serves to regulate vascular tone and to inhibit platelet function. NO is a potent anti-atherosclerotic molecule, as shown by an experimental study that shows that the integration of L-arginine reduces the progression of atherosclerosis. The generation of NO is reduced in patients with PAD and among the different mechanisms involved in the reduced generation of NO, the increase in oxidative stress could play a key role leading to accelerated degradation of NO or inhibition of NO synthase.
Increased serum levels of isoprostanes and autoantibodies against low-density oxidized lipoproteins confirm the increase in oxidative stress in these patients. Furthermore, the role of oxidative stress is confirmed by an intervention study in which PAD patients treated with propionyl-L-carnitine (6 g / day) for 7 days significantly increased the maximum distance traveled (MWD), an increase in bioavailability of NO and a reduction in oxidative stress.
The main risk factors involved in the onset of PAD include age, smoking, obesity, hyperlipemia and hypertension. Because hypertension is associated with the development of atherosclerosis, particularly in the coronary and cerebral circulation, it is also associated with an increased risk of developing PAD. In fact, of hypertensives at presentation, about 2-5% have intermittent claudication, with increasing prevalence with age. Otherwise, 35-55% of patients with PAD at presentation also show hypertension. Therefore, treatment of hypertension could lead to a reduction in the incidence of PAD. (PubMed ID:15579058) PAD patients have a risk of cardiovascular and cerebrovascular mortality increased two to three times compared to healthy subjects. The alteration of platelet function is implicated in the development and progression of atherosclerosis, as well as in the pathogenesis of acute cardiac ischemic events. Platelet activation is increased in patients with lower limb ischemia compared to healthy controls since it suggests a pro-thrombotic state.
Polyphenols are a class of natural, synthetic and semisynthetic molecules characterized by the presence of phenolic units. In recent decades, prospective and epidemiological studies that show potentially beneficial effects of these molecules on human health (for example on the cardiovascular and nervous systems). In particular, the polyphenols exert their beneficial effect through the inhibition of NADPH oxidase (Nox2), which is crucial for the formation of reactive oxygen species (ROS). There are several flavonoids that can exert antiplatelet effects for example by attenuating the process of platelet activation. Moreover, polyphenols can also exert beneficial effects through the activation of autophagy.
Autophagy is an intracellular cytoprotective process that mediates protein degradation, organelle turnover, and recycling of cytoplasmic components in conditions of nutrient deprivation and cellular stress (PubMed ID: 15068787). Furthermore, autophagy plays an important role in the removal of excess cellular ROS by maintaining a redox balance (PubMed ID: 27200146). The degraded materials in the autophagosome are then used for anabolic reactions, to sustain energy levels and provide simple molecules deriving from the degradation process that can be reused by cells for other functions. Autophagy, therefore, helps cells adapt to energy and stress changes by supporting cellular metabolism, homeostasis, and survival (PubMed ID: 18006683). The insufficient autophagic activity can contribute to cell death. Several studies have shown that inhibition of autophagic flow can contribute to the pathogenesis of cardiovascular diseases, diabetes, inflammatory disorders, cancer and physical stress (PubMed ID: 18191218).
Trehalose is a natural disaccharide composed of two glucose molecules linked by an α1-1-glycosidic bond, which is synthesized by lower organisms such as yeasts, insect bacteria, and plants but not by mammals. Trehalose performs multiple functions that distinguish it from other common disaccharides, including a protective action against various stressors, such as oxidative stress, temperature changes, accumulation of protein aggregates and dehydration (PubMed ID: 12626396). Furthermore, recent evidence has shown that trehalose could prevent inflammatory responses induced by endotoxic shock both in vivo and in vitro (PubMed ID: 17172986 and PubMed ID: 18555988). The oral administration of this disaccharide is able to drastically reduce the development and progression of neurodegenerative disorders, hepatic steatosis, renal damage, insulin resistance, atherosclerosis, post-ischemic cardiac remodelling and pancreatitis (PubMed ID: 22689910, PubMed ID: 21147367 and PubMed ID: 29724354) mainly through the stimulation of autophagy. Indeed, it has been shown that trehalose is a strong inducer of autophagy (PubMed ID: 17182613 ). Furthermore, our preliminary in vitro data showed that trehalose in combination with a mix of polyphenols (catechin and epicatechin) can reduce platelet activation, and oxidative stress and improves autophagic flow. Finally, we observed in the endothelial cells that the mix could increase the production of NO, angiogenetic property and cell viability.
- Conditions
- Oxidative Stress, Cardiovascular Diseases
- Being tested
- Supplementation with mix of threalose plus polyphenols, No Supplementation with mix of threalose plus polyphenols
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supplementation with mix of threalose plus polyphenolsOther
The patients will be treated with a mix of trehalose plus polyphenols for 60 days
No Supplementation with mix of threalose plus polyphenolsOther
The patients will not be treated with a mix trehalose plus polyphenols for 60 days
| Study group | Role | What they receive |
|---|---|---|
| No Intervention with the mix threalose plus polyphenols | Sham comparator | The patients allocated in this arm will not treated with a mix of threalose plus polyphenols Receives: Other: No Supplementation with mix of threalose plus polyphenols |
| Intervention with the mix threalose plus polyhenols | Active comparator | The patients allocated in this arm will treated with a mix of threalose plus polyphenols Receives: Other: Supplementation with mix of threalose plus polyphenols |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change o oxidative stress biomarkers in PAD patients after mix supplementation of trehalose and polyphenols
Oxidative stress biomarkers such as Nox2 activity (pg/ml) production will be measured. Differences of these markers among patients taking or not the supplementation will be described.
Measured: 12 months
Change o oxidative stress biomarkers in hypertensive patients after mix supplementation
To verify whether there is a reduction in the Nox2 activity in hypertensive patients after supplementation with the trehalose and polyphenols mix.
Measured: 12 months
Secondary outcomes (6)
Change of autophagy in PAD and hypertensive patients patients after mix supplementation of trehalose and polyphenols
Autophagy biomarkers such as LC3 (Arbitrary Unit) will be measured. Differences of this protein among patients taking or not the mix supplementation will be described. The relationship with oxidative stress markers will be described.
Measured: 12 months
Change of endothelial function in PAD and hypertensive patients after mix supplementation of trehalose and polyphenols
To assess changes in endothelial function evaluated by Flow Mediated Dilation (FMD, %) analysis in patients taking or not the mix supplementation. The relationship with oxidative stress and autophagy will be described.
Measured: 12 months
Change of systolic and diastolic pressure in PAD and hypertensive patients after mix supplementation of trehalose and polyphenols
To assess changes in systolic (mmHg) and diastolic (mmHg) pressure in patients taking or not the mix supplementation. The relationship with oxidative stress and autophagy will be described.
Measured: 12 months
Analysis of maximal walking distance (MWD) in PAD patients after mix supplementation of trehalose and polyphenols
To assess changes in MWD (meters) evaluated by treadmill test in patients taking or not the mix supplementation. The relationship with oxidative stress, autophagy and endothelial function will be described.
Measured: 12 months
Analysis of maximal walking time (MWT) in PAD
- assess changes in MWD (seconds) evaluated by treadmill test in patients taking or not the mix supplementation. The relationship with oxidative stress, autophagy and endothelial function will be described.
Measured: 12 months
Analysis of blood pressure in hypertensive patients after mix supplementation of trehalose and polyphenols
- assess changes in blood pressure in patients taking or not the mix supplementation. The relationship with oxidative stress, autophagy and endothelial function will be described.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2019
- Study start12 Dec 2019
- Primary completion30 Sep 2020
- Study completion30 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Oxidative StressStudies of the same condition, open and under way.
- More trials run by University of Roma La SapienzaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Roma La Sapienza
- Sponsor type
- University, hospital or other
- Collaborators
- Peruzzi Mariangela
- Responsible party
- Principal investigator, Pasquale Pignatelli, University of Roma La Sapienza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04061070
- Sponsor's protocol ID
- PAD2307/2019 and 454/2020
- Status last verified
- Mar 2020
- First submitted
- 24 Jul 2019
- Last updated
- 18 Jun 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3(3):241-5. doi: 10.1177/1358836X9800300311.
PubMed 9892517Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, Chiarotti F, Violi F. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J. 2007 Mar;28(5):608-12. doi: 10.1093/eurheartj/ehl533. Epub 2007 Feb 13.
PubMed 17298965Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutshinoff A, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino). 1989 Jan-Feb;30(1):50-7.
PubMed 2647761Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004 Apr;6(4):463-77. doi: 10.1016/s1534-5807(04)00099-1.
PubMed 15068787Li F, Lang F, Zhang H, Xu L, Wang Y, Hao E. Role of TFEB Mediated Autophagy, Oxidative Stress, Inflammation, and Cell Death in Endotoxin Induced Myocardial Toxicity of Young and Aged Mice. Oxid Med Cell Longev. 2016;2016:5380319. doi: 10.1155/2016/5380319. Epub 2016 Apr 21.
PubMed 27200146Mizushima N. Autophagy: process and function. Genes Dev. 2007 Nov 15;21(22):2861-73. doi: 10.1101/gad.1599207.
PubMed 18006683Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008 Jan 11;132(1):27-42. doi: 10.1016/j.cell.2007.12.018.
PubMed 18191218Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology. 2003 Apr;13(4):17R-27R. doi: 10.1093/glycob/cwg047. Epub 2003 Jan 22.
PubMed 12626396Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, Giuliani D, Fiumara T, Magazu S, Ruggeri P, Guarini S, Squadrito F. The disaccharide trehalose inhibits proinflammatory phenotype activation in macrophages and prevents mortality in experimental septic shock. Shock. 2007 Jan;27(1):91-6. doi: 10.1097/01.shk.0000235092.76292.bc.
PubMed 17172986Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, Fiumara T, Magazu S, Migliardo F, Venuti FS, Squadrito F. Retracted: Trehalose: a biophysics approach to modulate the inflammatory response during endotoxic shock. Eur J Pharmacol. 2008 Jul 28;589(1-3):272-80. doi: 10.1016/j.ejphar.2008.04.005. Epub 2008 Apr 12.
PubMed 18555988Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012 Jul;135(Pt 7):2169-77. doi: 10.1093/brain/aws143. Epub 2012 Jun 10.
PubMed 22689910Arai C, Arai N, Mizote A, Kohno K, Iwaki K, Hanaya T, Arai S, Ushio S, Fukuda S. Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance. Nutr Res. 2010 Dec;30(12):840-8. doi: 10.1016/j.nutres.2010.10.009.
PubMed 21147367Sciarretta S, Yee D, Nagarajan N, Bianchi F, Saito T, Valenti V, Tong M, Del Re DP, Vecchione C, Schirone L, Forte M, Rubattu S, Shirakabe A, Boppana VS, Volpe M, Frati G, Zhai P, Sadoshima J. Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction. J Am Coll Cardiol. 2018 May 8;71(18):1999-2010. doi: 10.1016/j.jacc.2018.02.066.
PubMed 29724354Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007 Feb 23;282(8):5641-52. doi: 10.1074/jbc.M609532200. Epub 2006 Dec 20.
PubMed 17182613Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des. 2004;10(29):3615-20. doi: 10.2174/1381612043382819.
PubMed 15579058
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Trehalose and a Mix of Polyphenols on Endothelial Function, Oxidative Stress, Platelet Function and Autophagy in Vasculopathic Patients
- ClinicalTrials.gov ID
- NCT04061070
- Acronym / sponsor ID
- PAD2307/2019 and 454/2020
- Conditions
- Oxidative Stress, Cardiovascular Diseases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- University of Roma La SapienzaUniversity, hospital or other
- Collaborators
- Peruzzi Mariangela
- Study start
- 12 Dec 2019 (actual)
- Primary completion
- 30 Sep 2020 (actual)
- Study completion
- 30 Apr 2021 (actual)
- First posted
- 19 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis and is characterized by obstruction of the arteries of the lower extremities. PAD is usually associated with vascular complications that occur not only in peripheral circulation but also in cerebral and coronary trees (PubMed ID: 9892517). Endothelial dysfunction, reduced glucose oxidation, accumulation of toxic metabolites, alteration in nitric oxide (NO) generation and oxidative stress seem to play a role among the factors that contribute to reducing blood flow in PAD patients (PubMed ID: 17298965).
Hypertension is a risk factor for vascular disorders, including PAD. In fact, it has been shown that 55% of PAD patients are hypertensive. (PubMed ID: 15579058) PAD and hypertension patients have a risk of cardiovascular and cerebrovascular mortality increased two to three times compared to healthy subjects. The alteration of platelet function is implicated in the development and progression of atherosclerosis, as well as in the pathogenesis of acute cardiac ischemic events. Platelet activation is increased in patients with PAD and hypertension compared to healthy controls, suggesting a pro-thrombotic state.
Polyphenols are a class of natural, synthetic and semisynthetic substances with beneficial effects on human health. In particular, the polyphenols exert their beneficial effect through 1) the inhibition of NADPH oxidase (Nox2), which is crucial for the formation of reactive oxygen species (ROS); 2) an antiplatelet effects 3) the activation of autophagy. Trehalose is a natural disaccharide that performs multiple functions such as a protective action against oxidative stress, temperature changes, accumulation of protein aggregates and dehydration. Furthermore, recent evidence has shown that trehalose could prevent inflammatory responses induced by endotoxic shock both in vivo and in vitro.
Therefore the purpose of this work will be to determine in PAD and hypertension patients the effect of the intake of trehalose and a polyphenol mix on oxidative stress biomarkers, autophagic activity and endothelial dysfunction.
Detailed description
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis and is characterized by obstruction of the arteries of the lower limbs. PAD is usually associated with vascular complications that occur not only in peripheral circulation but also in cerebral and coronary trees (PubMed ID: 9892517). Intermittent claudication, the typical clinical manifestation of the disease that affects about a third of PAD patients, is identified by an alteration in blood flow to the lower extremities during exercise, worsens in 25% of patients and about 5% suffers an amputation (PubMed ID: 2647761). Arteries, arterioles, and capillaries that serve the skeletal muscle tissue distal to the site of the stenosis play a key role in the onset of claudication. Endothelial dysfunction, reduced glucose oxidation, accumulation of toxic metabolites, alteration in nitric oxide (NO) generation and oxidative stress seem to play a role among the factors that contribute to reducing blood flow in PAD patients (PubMed ID: 17298965). Nitric oxide (NO) is synthesized by L-arginine, is constitutively released by endothelial cells and serves to regulate vascular tone and to inhibit platelet function. NO is a potent anti-atherosclerotic molecule, as shown by an experimental study that shows that the integration of L-arginine reduces the progression of atherosclerosis. The generation of NO is reduced in patients with PAD and among the different mechanisms involved in the reduced generation of NO, the increase in oxidative stress could play a key role leading to accelerated degradation of NO or inhibition of NO synthase.
Increased serum levels of isoprostanes and autoantibodies against low-density oxidized lipoproteins confirm the increase in oxidative stress in these patients. Furthermore, the role of oxidative stress is confirmed by an intervention study in which PAD patients treated with propionyl-L-carnitine (6 g / day) for 7 days significantly increased the maximum distance traveled (MWD), an increase in bioavailability of NO and a reduction in oxidative stress.
The main risk factors involved in the onset of PAD include age, smoking, obesity, hyperlipemia and hypertension. Because hypertension is associated with the development of atherosclerosis, particularly in the coronary and cerebral circulation, it is also associated with an increased risk of developing PAD. In fact, of hypertensives at presentation, about 2-5% have intermittent claudication, with increasing prevalence with age. Otherwise, 35-55% of patients with PAD at presentation also show hypertension. Therefore, treatment of hypertension could lead to a reduction in the incidence of PAD. (PubMed ID:15579058) PAD patients have a risk of cardiovascular and cerebrovascular mortality increased two to three times compared to healthy subjects. The alteration of platelet function is implicated in the development and progression of atherosclerosis, as well as in the pathogenesis of acute cardiac ischemic events. Platelet activation is increased in patients with lower limb ischemia compared to healthy controls since it suggests a pro-thrombotic state.
Polyphenols are a class of natural, synthetic and semisynthetic molecules characterized by the presence of phenolic units. In recent decades, prospective and epidemiological studies that show potentially beneficial effects of these molecules on human health (for example on the cardiovascular and nervous systems). In particular, the polyphenols exert their beneficial effect through the inhibition of NADPH oxidase (Nox2), which is crucial for the formation of reactive oxygen species (ROS). There are several flavonoids that can exert antiplatelet effects for example by attenuating the process of platelet activation. Moreover, polyphenols can also exert beneficial effects through the activation of autophagy.
Autophagy is an intracellular cytoprotective process that mediates protein degradation, organelle turnover, and recycling of cytoplasmic components in conditions of nutrient deprivation and cellular stress (PubMed ID: 15068787). Furthermore, autophagy plays an important role in the removal of excess cellular ROS by maintaining a redox balance (PubMed ID: 27200146). The degraded materials in the autophagosome are then used for anabolic reactions, to sustain energy levels and provide simple molecules deriving from the degradation process that can be reused by cells for other functions. Autophagy, therefore, helps cells adapt to energy and stress changes by supporting cellular metabolism, homeostasis, and survival (PubMed ID: 18006683). The insufficient autophagic activity can contribute to cell death. Several studies have shown that inhibition of autophagic flow can contribute to the pathogenesis of cardiovascular diseases, diabetes, inflammatory disorders, cancer and physical stress (PubMed ID: 18191218).
Trehalose is a natural disaccharide composed of two glucose molecules linked by an α1-1-glycosidic bond, which is synthesized by lower organisms such as yeasts, insect bacteria, and plants but not by mammals. Trehalose performs multiple functions that distinguish it from other common disaccharides, including a protective action against various stressors, such as oxidative stress, temperature changes, accumulation of protein aggregates and dehydration (PubMed ID: 12626396). Furthermore, recent evidence has shown that trehalose could prevent inflammatory responses induced by endotoxic shock both in vivo and in vitro (PubMed ID: 17172986 and PubMed ID: 18555988). The oral administration of this disaccharide is able to drastically reduce the development and progression of neurodegenerative disorders, hepatic steatosis, renal damage, insulin resistance, atherosclerosis, post-ischemic cardiac remodelling and pancreatitis (PubMed ID: 22689910, PubMed ID: 21147367 and PubMed ID: 29724354) mainly through the stimulation of autophagy. Indeed, it has been shown that trehalose is a strong inducer of autophagy (PubMed ID: 17182613 ). Furthermore, our preliminary in vitro data showed that trehalose in combination with a mix of polyphenols (catechin and epicatechin) can reduce platelet activation, and oxidative stress and improves autophagic flow. Finally, we observed in the endothelial cells that the mix could increase the production of NO, angiogenetic property and cell viability.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| No Intervention with the mix threalose plus polyphenols | Sham comparator | Other: No Supplementation with mix of threalose plus polyphenolsThe patients allocated in this arm will not treated with a mix of threalose plus polyphenols |
| Intervention with the mix threalose plus polyhenols | Active comparator | Other: Supplementation with mix of threalose plus polyphenolsThe patients allocated in this arm will treated with a mix of threalose plus polyphenols |
Who may qualify
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- claudication (defined as pain in the legs during walking which disappears within 10 minutes of standing);
- ankle/brachial index (ABI), evaluated as an ankle/arm systolic blood pressure ratio using Doppler ultrasound on the worst resting leg;
- stable condition without sudden changes in ABI (> 20%) in the last month before enrollment
- Office systolic BP (SBP) values ≥140 mmHg and/or diastolic BP (DBP) values ≥90 mmHg (average of 3 repeated measurements made by the same doctor with an oscillometric automatic sphygmomanometer). Treatment with antihypertensive drugs, namely ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), thiazide/thiazide-like diuretics, loop diuretics, mineralocorticoid receptor antagonists (MRA), beta-blockers and alpha-blockers, were considered hypertensives.
Key exclusion criteria (7 listed)
- liver failure;
- severe kidney disorders (serum creatinine [mt] 2.8 mg / dL);
- acute cerebrovascular disease;
- acute myocardial infarction;
- smokers;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supplementation with mix of threalose plus polyphenolsThe patients will be treated with a mix of trehalose plus polyphenols for 60 days | Other | Intervention with the mix threalose plus polyhenols |
| No Supplementation with mix of threalose plus polyphenolsThe patients will not be treated with a mix trehalose plus polyphenols for 60 days | Other | No Intervention with the mix threalose plus polyphenols |
Primary outcome
Change o oxidative stress biomarkers in PAD patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Oxidative stress biomarkers such as Nox2 activity (pg/ml) production will be measured. Differences of these markers among patients taking or not the supplementation will be described.
Change o oxidative stress biomarkers in hypertensive patients after mix supplementation
Time frame: 12 months
To verify whether there is a reduction in the Nox2 activity in hypertensive patients after supplementation with the trehalose and polyphenols mix.
6 secondary outcomes
Change of autophagy in PAD and hypertensive patients patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Change of endothelial function in PAD and hypertensive patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Change of systolic and diastolic pressure in PAD and hypertensive patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Analysis of maximal walking distance (MWD) in PAD patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Analysis of maximal walking time (MWT) in PAD
Time frame: 12 months
Analysis of blood pressure in hypertensive patients after mix supplementation of trehalose and polyphenols
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2023.
- Results publication: PubMed 9892517Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3(3):241-5. doi: 10.1177/1358836X9800300311.
- Results publication: PubMed 17298965Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, Chiarotti F, Violi F. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J. 2007 Mar;28(5):608-12. doi: 10.1093/eurheartj/ehl533. Epub 2007 Feb 13.
- Results publication: PubMed 2647761Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutshinoff A, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino). 1989 Jan-Feb;30(1):50-7.
- Results publication: PubMed 15068787Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004 Apr;6(4):463-77. doi: 10.1016/s1534-5807(04)00099-1.
- Results publication: PubMed 27200146Li F, Lang F, Zhang H, Xu L, Wang Y, Hao E. Role of TFEB Mediated Autophagy, Oxidative Stress, Inflammation, and Cell Death in Endotoxin Induced Myocardial Toxicity of Young and Aged Mice. Oxid Med Cell Longev. 2016;2016:5380319. doi: 10.1155/2016/5380319. Epub 2016 Apr 21.
- Results publication: PubMed 18006683Mizushima N. Autophagy: process and function. Genes Dev. 2007 Nov 15;21(22):2861-73. doi: 10.1101/gad.1599207.
- Results publication: PubMed 18191218Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008 Jan 11;132(1):27-42. doi: 10.1016/j.cell.2007.12.018.
- Results publication: PubMed 12626396Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology. 2003 Apr;13(4):17R-27R. doi: 10.1093/glycob/cwg047. Epub 2003 Jan 22.
- Results publication: PubMed 17172986Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, Giuliani D, Fiumara T, Magazu S, Ruggeri P, Guarini S, Squadrito F. The disaccharide trehalose inhibits proinflammatory phenotype activation in macrophages and prevents mortality in experimental septic shock. Shock. 2007 Jan;27(1):91-6. doi: 10.1097/01.shk.0000235092.76292.bc.
- Results publication: PubMed 18555988Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, Fiumara T, Magazu S, Migliardo F, Venuti FS, Squadrito F. Retracted: Trehalose: a biophysics approach to modulate the inflammatory response during endotoxic shock. Eur J Pharmacol. 2008 Jul 28;589(1-3):272-80. doi: 10.1016/j.ejphar.2008.04.005. Epub 2008 Apr 12.
- Results publication: PubMed 22689910Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012 Jul;135(Pt 7):2169-77. doi: 10.1093/brain/aws143. Epub 2012 Jun 10.
- Results publication: PubMed 21147367Arai C, Arai N, Mizote A, Kohno K, Iwaki K, Hanaya T, Arai S, Ushio S, Fukuda S. Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance. Nutr Res. 2010 Dec;30(12):840-8. doi: 10.1016/j.nutres.2010.10.009.
- Individual participant dataSharing planned: No
Related trials for Oxidative Stress
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Recruiting
Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
Athletic Performance, Hyperbaric Oxygenation
Recruiting
Dietary Intervention Study on Liver Health in Young Adults
Liver Health
RecruitingObservational study
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Gaucher Disease Type I, Oxidative Stress
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supplementation with mix of threalose plus polyphenols and No Supplementation with mix of threalose plus polyphenols in people with Oxidative Stress and Cardiovascular Diseases, run by University of Roma La Sapienza at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change o oxidative stress biomarkers in PAD patients after mix supplementation of trehalose and polyphenols (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04061070, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2023.